Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Shares Outstanding (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 3 years of Shares Outstanding data on record, last reported at $71.0 million in Q1 2024.

  • For Q1 2024, Shares Outstanding rose 19.47% year-over-year to $71.0 million; the TTM value through Mar 2024 reached $71.0 million, up 19.47%, while the annual FY2023 figure was $70.8 million, 19.38% up from the prior year.
  • Shares Outstanding reached $71.0 million in Q1 2024 per ZNTL's latest filing, roughly flat from $70.8 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $71.0 million in Q1 2024 and bottomed at $45.6 million in Q1 2022.
  • Average Shares Outstanding over 3 years is $62.4 million, with a median of $59.4 million recorded in 2023.
  • The widest YoY moves for Shares Outstanding: up 30.4% in 2023, down 19.38% in 2023.
  • A 3-year view of Shares Outstanding shows it stood at $59.3 million in 2022, then grew by 19.38% to $70.8 million in 2023, then grew by 0.35% to $71.0 million in 2024.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $71.0 million in Q1 2024, $70.8 million in Q4 2023, and $70.6 million in Q3 2023.